BILIARY ATRESIA TREATMENT MARKET ANALYSIS

Market Challenges And Opportunities

Global Biliary Atresia Treatment Market– Impact of Coronavirus (COVID-19) Pandemic

Due to the COVID-19 pandemic, pediatric liver research has faced a lot of challenges. The most impacted have been clinical research studies focusing on rare diseases like biliary atresia (BA), which is the most common indication for liver transplantation.

Biliary atresia studies done under the ‘The Childhood Liver Disease Research Network’ (ChiLDReN), an NIH-funded consortium and biorepository, has been largely interrupted during this COVID-19 pandemic, as there has been no new sample collection. Due to the failure to capture new cases of BA, the timeline of research progress will certainly be prolonged. Moreover, the diagnosis of BA has been delayed, as parents are scared of bringing their infants to their pediatrician’s hospital during this period for BA diagnosis.

As several pediatric liver diseases fall under the category of rare diseases, the unstable economic times and greatest impact of this pandemic on funding of pediatric liver research may be seen.

Global Biliary Atresia Treatment Market: Restraint

The major factors that hinder the growth of the global biliary atresia treatment market include safety concerns related to the drug, higher cost involved in the treatment, limited treatment options, and lack of skilled professional in some developing countries like India, Kenya and others.